• A cancer cell line is a population of cancer cells that can be grown in a lab.

Why can it be grown forever?

  • Normal scells stop dividing after a few rounds (called senescence).
  • Cancer cells often have mutations that allow them to bypass normal limits on growth.
  • These cells can grow into petri dishes or flasks, a process known as cell culture.

History of first cancer cell line: HeLa cell

  • First successfully grew in 1951
  • Source: derived from a cervical cancer tumor of Henrietta Lacks, a young African American woman passed away from the disease that year.
  • Location: Johns Jopkins Hospital, Baltimore, MD.
  • Scientist: Dr. George Gey.
  • First human cells grown to divide indefinitely.
  • Revolutionized biomedical research.

Why use cell lines?

  • easy to grow and manipulate in the lab
  • Represent various human cancers (e.g., breast, lung, colon).
  • Serve as models to: study tumor genetics, discover cancer vulnerabilities, test therapeutic compounds

Cancer cell lines

  • used to study Molecular Mechanism of Cancer Cells
  • Study signaling pathways in caner (e.g., PI3K/AKT, RAS/MAPK, Wnt).
  • Knockwdown or overexpress genes to observe functional changes.
  • Investigate the role of oncogenes (e.g., KRAS, MYC) or tumor suppressors (e.g., TP53, RB1)

Modeling specific cancer subtypes

  • Cancers are geterogenous diseases. For example, breast cancers have different subtypes.
  • Subtypes are defined based on the presence orr absence of certain receptors and gene expression profiles
  • Main breast cancer subtypes based on the presence of receptors
    • Luminal A (ER+, PR+, HER2-): best prognosis
    • Luminal B (ER+, PR+-, HER+-), moderate
    • HER2+ (ER-, PR-, HER2+)
    • Triple negative (ER-, PR-, HER2-); poor pronosis

Development of PAM50 classifier

  • 2009 - parket et al., in Journal of Clinical Oncology
    • refined Perou’s gene set to 50 genes (PAM50) for clinical use.
    • Classified tumors into the same 5 subtypes using qRT-PCR/NanoString
    • These subtypes can guide the choice of therapy
    • Also introduced Risk of Recurrence (ROR) score.
  • Led to the clinical test Prosigna, used in ER+/HER2- breast cancer.
  • Prosigna diagnostic assay was developed and commercialiozed by NanoString Technologies, Inc.
  • Dr. Charles perou, now a professor at UNC-Chapel is the co-inventor for Prosigna.

NanoStrongs Tehcnologies Inc

  • A bioteceh company, founded in 2003, under the leadership of Dr. Leroy Hood (spun off as an independent company)
  • Technology platforms:
  • nCounter: a digital gene expression platform that uses color-coded molecular barcodes to directly count RNA, DNA
  • Prosigna Assay: a FDA-cleared diagnostic teset for early-stage, hormone receptor-positive breast cancer based on the PAM50 gene signature
  • GeoMx Digital Spatial Profiler (DSP): A spatial transcriptomics and protemics platform launched in 2019.
  • began in 2003 with early seed funding (~$3.8M).
  • In 2012, a crucial Series E of $15.3M helped fund Prosigna development
  • IPO in mid-2013 raised $54M, culminating in about $82M total funding before becoming a public company
  • 2021-2023: faced lawsuits from 10xGenomics
  • 2024: Filed for Chapter 11 bankruptcy, assets sold off
  • Bruker Corporation, a global leader in life0science instrumentation, acquired its assets at $392.6M (nCounter, GeoMx, CosMx, AtoMx, Prosigna)
  • Bruker aims to integrate NanoString’s gene expression and spatial biology platforms into its broader CellScape proteomics systems

What is CCLE?

  • A public resource of cancer cell lines developed by the Broad Institute
  • Contains multi-omics data (genomic, transcriptomic, proteomic, pharmacologic).
    • genomic = DNA, transcriptomic = RNA, proteomic = protein
  • Used to study cancer biology and predict drug sensitivity.

Drug screening using cancer cell lines

  • To evaluate the efficacy, potency, and selectivity of drugs against different cancer types.
  • First, select cell lines
  • Seed cell line into multo-well plates (96-well, 384-well). Allow cells adhere and grow to a certain density under standard conditions.
  • A library of canditate drugs (or concentrations of a drug) is applied to cells.
  • Cells are incubated with drugs for 24-72 hours (or more)
  • Assay Readouts (viability, apoptosis, and proliferation) and data analysis: Generate Dose-Response Curves

What is a drug does response curve?

  • Dose-response graphs typically have the dose on the x-axis and the measured effect (i.e. the measured response) on the y-axis. Plotting the logarithm of the concentration generally results in sigmoidal plots.
  • The main parameters that can be identified by dose-response curves are:
    • Potency - the position of the curve along the x-axis
    • Maximal efficacy - the greatest response attainable
    • Slope - change in response per unit dose

What drug sensitivity data available?

  • The Cancer Cell Line Encyclopedia (CCLE), through teh DepMap portal, provides drug sensitivity data from several large-scale screening projects.
  • PRISM Repurposing Dataset (Broad Institute)
    • Pooled barcoded screening of ~500 cell lines
    • 4,500 compounds (many FDA-approved or invesetigational)

    • Relative viability (log fold change) at multiple concentrations

Breast cancer drugs on the market

  • Chemotherapy: doxorubicin; paclitaxel
  • Hormone therapy: tamoxifen, Anastrozole (Arimidex), exemestane (Aromasin)
  • Targeted therapy: trastuzumab, pertuzumab, and palbociclib

Information About my Jupyter Notebook

We were able to filter out specific cancers in the CCLE dataset. I filtered out breast and skin cancer, and I was able to find the different subtypes in breast cancer as well. However, I could not filter the different subtypes for skin cancer because the data had not been updated yet. But, I was able to find the Oncotree Subtype for skin cancer because that information is in the data table.

My Jupyter Notebook


<
Previous Post
Mutationcharts
>
Next Post
Liquid Biopsy for Cancer Metastasis Detections